Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 5Completed 2Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gastrointestinal 1Breast 1

Conditions

Primary Myelofibrosis 9Myeloproliferative Disorders 5Polycythemia Vera 4Thrombocythemia, Essential 3Neoplasms 3Leukemia, Myeloid, Acute 3Leukemia 3Recurrence 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Myelodysplastic Syndromes 2Lymphoma, Non-Hodgkin 2Leukemia, Myelomonocytic, Chronic 2Leukemia, Myeloid, Chronic-Phase 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Breast Neoplasms 2Uveal Melanoma 1Triple Negative Breast Neoplasms 1Thalassemia 1Pancreatic Neoplasms 1Other Cancer 1Mesothelioma 1Melanoma 1Lymphoma, Follicular 1Lymphoma 1Lung Neoplasms 1Leukemia, Lymphocytic, Chronic, B-Cell 1Inflammatory Breast Neoplasms 1Hypereosinophilic Syndrome 1Graft vs Host Disease 1Exanthema 1

Interventions

Gemcitabine 42130-nm albumin-bound paclitaxel 26Albumin-Bound Paclitaxel 18Irinotecan 16Oxaliplatin 14Fluorouracil 14pembrolizumab 13Nivolumab 13Magnetic Resonance Spectroscopy 11Leucovorin 11Taxes 10Specimen Handling 9Biopsy 9Cisplatin 8Capecitabine 7folfirinox 6Radiotherapy 6Carboplatin 6irinotecan sucrosofate 5durvalumab 5Ipilimumab 5Cyclophosphamide 5olaparib 4defactinib 4Surveys and Questionnaires 4Standard of Care 4Radiosurgery 4Immunoglobulin G 4Disulfides 4dehydroftorafur 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Pancreatic Neoplasms × ruxolitinib × Clear all
NCT02955940 2025-12-17

An Open-Label Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of Ruxolitinib

Incyte Corporation

Phase 2 Active not recruiting
10 enrolled
BreastGastrointestinalThoracic

Breast Neoplasms, Lung Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡